34766133|t|Roles of hepatic atypical protein kinase C hyperactivity and hyperinsulinemia in insulin-resistant forms of obesity and type 2 diabetes mellitus.
34766133|a|Diet-induced obesity, the metabolic syndrome, type 2 diabetes (DIO/MetS/T2DM), and their adverse sequelae have reached pandemic levels. In mice, DIO/MetS/T2DM initiation involves diet-dependent increases in lipids that activate hepatic atypical PKC (aPKC) and thereby increase lipogenic enzymes and proinflammatory cytokines. These or other hepatic aberrations, via adverse liver-to-muscle cross talk, rapidly impair postreceptor insulin signaling to glucose transport in muscle. The ensuing hyperinsulinemia further activates hepatic aPKC, which first blocks the ability of Akt to suppress gluconeogenic enzyme expression, and later impairs Akt activation, further increasing hepatic glucose production. Recent findings suggest that hepatic aPKC also increases a proteolytic enzyme that degrades insulin receptors. Fortunately, all hepatic aberrations and muscle impairments are prevented/reversed by inhibition or deficiency of hepatic aPKC. But, in the absence of treatment, hyperinsulinemia induces adverse events, some by using "spare receptors" to bypass receptor defects. Thus, in brain, hyperinsulinemia increases Abeta-plaque precursors and Alzheimer risk; in kidney, hyperinsulinemia activates the renin-angiotensin-adrenal axis, thus increasing vasoconstriction, sodium retention, and cardiovascular risk; and in liver, hyperinsulinemia increases lipogenesis, obesity, hepatosteatosis, hyperlipidemia, and cardiovascular risk. In summary, increases in hepatic aPKC are critically required for development of DIO/MetS/T2DM and its adverse sequelae, and therapeutic approaches that limit hepatic aPKC may be particularly effective.
34766133	61	77	hyperinsulinemia	Disease	MESH:D006946
34766133	108	115	obesity	Disease	MESH:D009765
34766133	120	144	type 2 diabetes mellitus	Disease	MESH:D003924
34766133	159	166	obesity	Disease	MESH:D009765
34766133	172	190	metabolic syndrome	Disease	MESH:D024821
34766133	192	207	type 2 diabetes	Disease	MESH:D003924
34766133	209	212	DIO	Disease	
34766133	213	217	MetS	Disease	
34766133	218	222	T2DM	Disease	
34766133	285	289	mice	Species	10090
34766133	291	294	DIO	Chemical	-
34766133	295	299	MetS	Disease	
34766133	300	304	T2DM	Disease	
34766133	353	359	lipids	Chemical	MESH:D008055
34766133	487	506	hepatic aberrations	Disease	MESH:D002869
34766133	597	604	glucose	Chemical	MESH:D005947
34766133	638	654	hyperinsulinemia	Disease	MESH:D006946
34766133	721	724	Akt	Gene	11651
34766133	788	791	Akt	Gene	11651
34766133	831	838	glucose	Chemical	MESH:D005947
34766133	979	998	hepatic aberrations	Disease	MESH:D002869
34766133	1003	1021	muscle impairments	Disease	MESH:D009135
34766133	1124	1140	hyperinsulinemia	Disease	MESH:D006946
34766133	1241	1257	hyperinsulinemia	Disease	MESH:D006946
34766133	1268	1273	Abeta	Gene	11820
34766133	1296	1305	Alzheimer	Disease	MESH:D000544
34766133	1323	1339	hyperinsulinemia	Disease	MESH:D006946
34766133	1420	1426	sodium	Chemical	MESH:D012964
34766133	1477	1493	hyperinsulinemia	Disease	MESH:D006946
34766133	1517	1524	obesity	Disease	MESH:D009765
34766133	1526	1541	hepatosteatosis	Disease	
34766133	1543	1557	hyperlipidemia	Disease	MESH:D006949
34766133	1665	1668	DIO	Disease	
34766133	1669	1673	MetS	Disease	
34766133	1674	1678	T2DM	Disease	
34766133	Positive_Correlation	MESH:D005947	MESH:D006946
34766133	Association	MESH:D005947	MESH:D002869
34766133	Negative_Correlation	MESH:D006946	11651
34766133	Positive_Correlation	MESH:D006946	11820

